Lakefront Biotherapeutics (LKFT) Net Income towards Common Stockholders (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Net Income towards Common Stockholders for 13 consecutive years, with $17.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 110.51% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at $571.4 million (up 417.42% YoY), while the FY2025 annual figure was $373.5 million, up 371.84% from the prior year.
• Net Income towards Common Stockholders slipped to $17.0 million in Q1 2026 per LKFT's latest filing, from $910.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $910.5 million in Q4 2025 and bottomed at -$236.3 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged $29.0 million across 5 years, with a median of $9.7 million in 2024.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 3266.69% in 2025 and fell as far as 1337.22% in 2025.
• Lakefront Biotherapeutics' Net Income towards Common Stockholders stood at -$211.4 million in 2022, then surged by 180.19% to $169.5 million in 2023, then sank by 84.05% to $27.0 million in 2024, then jumped by 3266.69% to $910.5 million in 2025, then tumbled by 98.14% to $17.0 million in 2026.
• Business Quant data shows LKFT's Net Income towards Common Stockholders at $17.0 million in Q1 2026, $910.5 million in Q4 2025, and -$236.3 million in Q3 2025.